Clinical Report: Cost-Effectiveness of Fibromyalgia Treatments

Overview

Duloxetine 120 mg demonstrates superior quality-adjusted life-years (QALYs) compared to amitriptyline in patients with moderate to severe fibromyalgia, according to a decision analytical model. The findings suggest that duloxetine offers greater economic value while accounting for societal costs.

Background

Fibromyalgia is a prevalent chronic pain condition that significantly impacts quality of life and healthcare costs. Effective management is crucial, particularly as the condition disproportionately affects women and is associated with various comorbidities. Understanding the cost-effectiveness of treatment options can guide clinical decision-making and resource allocation.

Data Highlights

Key Findings

Clinical Implications

Clinicians should consider duloxetine 120 mg as a first-line pharmacologic option for managing moderate to severe fibromyalgia due to its favorable cost-effectiveness profile. The findings underscore the importance of incorporating societal costs into treatment decisions to optimize patient outcomes.

Conclusion

Duloxetine 120 mg offers the greatest economic value among the tested treatments for fibromyalgia, highlighting its potential as a preferred option in clinical practice. Further research is needed to validate these findings in real-world settings.

References

1. Downen SS, et al., JAMA Network Open, 2026 -- Cost-Effectiveness of Pregabalin, Duloxetine, and Milnacipran vs Amitriptyline for Moderate to Severe Fibromyalgia
2. Clinical Rheumatology, 2017 -- Investigating the Placebo Effect and Its Influencing Factors in Fibromyalgia: A Meta-Analysis of Randomized Controlled Trials
3. Pain Medicine, 2023 -- Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine
4. Clinical Rheumatology, 2009 -- Evaluation of the safety and tolerability of duloxetine for fibromyalgia management: a comprehensive analysis of data from five clinical studies
5. EULAR revised recommendations for the management of fibromyalgia - PubMed, 2017
6. Good Evidence That Duloxetine, Milnacipran, and Pregabalin Provide Meaningful Pain Reduction in Adults With Fibromyalgia | AAFP, 2025
7. conexiant — TENS Added to Physical Therapy Lowers Fibromyalgia Pain
8. EULAR revised recommendations for the management of fibromyalgia - PubMed
9. Good Evidence That Duloxetine, Milnacipran, and Pregabalin Provide Meaningful Pain Reduction in Adults With Fibromyalgia | AAFP
10. Cost-Effectiveness of Pregabalin, Duloxetine, and Milnacipran vs Amitriptyline for Moderate to Severe Fibromyalgia | Rheumatology | JAMA Network Open | JAMA Network